IFN beta 1 (AA 22-182) (Active) Protein

Catalog No. ABIN2666650

This Recombinant IFN beta 1 protein is produced in HEK-293 Cells.

Quick Overview for IFN beta 1 (AA 22-182) (Active) Protein (ABIN2666650)

Target: IFN beta 1

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: HEK-293 Cells

Application: Flow Cytometry (FACS)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 22-182

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: IFN-β1 bioactivity was measured by its property to protect L929 cells from the cytopathic effect (CPE) of encephalomyocarditis virus (EMCV) in a dose dependent manner. The specific activity is 5.1 x 107 units/mg.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored from -20 °C to -70 °C. Stock solutions can also be prepared at 50-100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2-1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Target Details

Target: IFN beta 1

Alternative Name: IFN-Beta1

Background: IFN-β1 is part of the type I IFN multigene family which includes at least eight subclases: IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ω, IFN-τ, IFN-δ, and IFN-ζ (limitin). Type I interferons (IFNs) (alpha/beta interferon [IFN-α/β]) are expressed as a first line of defense against viruses and play a critical role in the antiviral response. The antiviral activity of type I IFNs is exerted by different mechanisms, e.g. blockage of viral entry into the cell, control of viral transcription, cleavage of RNA, and preventing translation, therefore, type I IFNs block virus replication. In addition, type I INFs modulate the innate and adaptive immune responses. IFN-α/β induces natural killer cell cytotoxicity and expression of major histocompatibility complex class I on most cells and costimulatory molecules on antigen-presenting cells. Also, type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. Plasmacytoid dendritic cells (pDCs) produce high amounts of type I interferons (IFNs) and a variety of inflammatory cytokines and chemokines in response to viral infections. Mice deficient for IFN-β type I IFN receptor (IFNAR) have demonstrated an increased susceptibility to experimental autoimmune encephalomyelitis (EAE). Animal studies have shown that neutralization of IL-23 or the lack of IL-23 p19 gene expression completely ameliorated EAE. These data correlate with the fact that IFN-β has been used in the treatment of multiple sclerosis (MS) in humans, and it has been suggested that IFN-β inhibits human Th17 cell differentiation. It is known that Th17 cells play a central role in the immunopathogenesis of MS, and IL-23 plays a role in the expansion of differentiated TL17 cells in mice and differentiation of Th17 cells in humans.

Molecular Weight: The 175 amino acid recombinant protein has a predicted molecular mass of approximately 21.2 kDa. The DTT-reduced and non-reduced protein migrates at approximately 36 kDa by SDS-PAGE. The N-terminal amino acid is Ile.